<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039944</url>
  </required_header>
  <id_info>
    <org_study_id>SI-B001_211</org_study_id>
    <nct_id>NCT05039944</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies</brief_title>
  <official_title>A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Unresectable or Metastatic Digestive System Malignancies (Colorectal and Gastric Cancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Evaluation of effectiveness: To further evaluate the effectiveness of SI-B001&#xD;
           monotherapy RP2D in patients with unresectable or metastatic colorectal cancer and&#xD;
           gastric cancer;To evaluate the efficacy of SI-B001 RP2D and sublow dose combined with&#xD;
           chemotherapy in patients with unresectable or metastatic colorectal cancer；&#xD;
&#xD;
        2. Evaluation of safety and tolerability: To further evaluate the safety and tolerability&#xD;
           of SI-B001 single-agent RP2D in patients with unresectable or metastatic colorectal&#xD;
           cancer and gastric cancer;To evaluate the safety and tolerability of SI-B001 RP2D and&#xD;
           sublow dose combined with chemotherapy in patients with unresectable or metastatic&#xD;
           colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>SI-B001_A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unresectable or metastatic gastric cancer, HER2-negative and without standard treatment were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI-B001_B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed conventional chemotherapy combined with EGFR mab were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI-B001_C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed multiple lines of conventional chemotherapy (excluding EGFR monoclonal antibody) were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI-B001 combined with irinetecan_D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI-B001 combined with FOLFIRI or FOLFOX_E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SI-B001 combined with irinetecan_F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI-B001</intervention_name>
    <description>Administration by intravenous infusion</description>
    <arm_group_label>SI-B001 combined with FOLFIRI or FOLFOX_E</arm_group_label>
    <arm_group_label>SI-B001 combined with irinetecan_D</arm_group_label>
    <arm_group_label>SI-B001 combined with irinetecan_F</arm_group_label>
    <arm_group_label>SI-B001_A</arm_group_label>
    <arm_group_label>SI-B001_B</arm_group_label>
    <arm_group_label>SI-B001_C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Administration by intravenous infusion</description>
    <arm_group_label>SI-B001 combined with irinetecan_D</arm_group_label>
    <arm_group_label>SI-B001 combined with irinetecan_F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI Protocol</intervention_name>
    <description>Administration by intravenous infusion</description>
    <arm_group_label>SI-B001 combined with FOLFIRI or FOLFOX_E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfox Protocol</intervention_name>
    <description>Administration by intravenous infusion</description>
    <arm_group_label>SI-B001 combined with FOLFIRI or FOLFOX_E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age ≥18;&#xD;
&#xD;
          2. Expected survival time ≥3 months;&#xD;
&#xD;
          3. Patients with unresectable or metastatic colorectal cancer or gastric cancer confirmed&#xD;
             by histology or pathology:&#xD;
&#xD;
             Cohort_A: Patients with unresectable or metastatic gastric cancer, HER2-negative,&#xD;
             without standard treatment.&#xD;
&#xD;
             Cohort_B: Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal&#xD;
             cancer, failure of conventional chemotherapy combined with EGFR mab, and withdrawal of&#xD;
             EGFR mab for less than 3 months.&#xD;
&#xD;
             Cohort_C: MSS KRASwt BRAFwt patients with unresectable or metastatic colorectal cancer&#xD;
             who have failed multiline conventional chemotherapy (without EGFR monoclonal antibody&#xD;
             therapy).&#xD;
&#xD;
             Cohort_D: MSI-H KRASwt BRAFwt patients with unresectable or metastatic colorectal&#xD;
             cancer and previous first - or second-line treatment failure with anti-PD-1 (L1) mab&#xD;
             (excluding EGFR mab).&#xD;
&#xD;
             Cohort_E: MSI-H KRASwt BRAFwt patients with unresectable or metastatic colorectal&#xD;
             cancer who have previously failed first-line anti-PD-1 (L1) mab therapy.&#xD;
&#xD;
             Cohort_F: MSS KRASwt BRAFwt patients with unresectable or metastatic colorectal cancer&#xD;
             who have failed standard therapy with first-line oxaliplatin or irinotecan plus&#xD;
             fluorouracil plus or minus bevacizumab.&#xD;
&#xD;
          4. No previous anti-EGFR antibody therapy (excluding Cohort_B);&#xD;
&#xD;
          5. Agree to provide 4 specimens (thickness 5μm) of tumor tissue specimens (non-stained&#xD;
             sections (anti-removal)) archiving from primary or metastatic tumors;agree to provide&#xD;
             6 unstained sections surgical specimens (anti-removal, thickness 10μm) or fresh tissue&#xD;
             samples;&#xD;
&#xD;
          6. There must be at least one measurable lesion conforming to the RECIST V1.1 definition;&#xD;
&#xD;
          7. Cohort_A, B, C fitness scores ≤2, Cohort_D, E, F fitness scores ≤1;&#xD;
&#xD;
          8. Toxicity of previous antitumor therapy has been restored to ≤1 as defined by NCI-CTCAE&#xD;
             V5.0 (except for toxicity that the researchers judge to be of no safety risk, such as&#xD;
             hair loss, grade 2 peripheral neurotoxicity, and stabilized hypothyroidism after&#xD;
             hormone replacement therapy);&#xD;
&#xD;
          9. Organ function levels must meet the following requirements and meet the following&#xD;
             standards:&#xD;
&#xD;
             A) Bone marrow function: absolute value of neutrophil count (ANC) ≥1.5×109/L, platelet&#xD;
             count ≥100×109/L (platelet count ≥75×109/L in Patients with Cohort_A, B and C),&#xD;
             hemoglobin ≥90 g/L (hemoglobin ≥85 g/L in patients with Cohort_A, B and C); B) Liver&#xD;
             function: Total bilirubin TBIL≤1.5×ULN (total bilirubin TBIL≤ 3×ULN in Gilbert's&#xD;
             syndrome, liver cancer or liver metastases); AST and ALT ≤2.5×ULN in patients without&#xD;
             liver metastasis; AST and ALT ≤5.0×ULN in patients with liver metastasis; C) Renal&#xD;
             function: Creatinine (Cr) ≤1.5×ULN, or creatinine clearance (Ccr) ≥50 mL/min&#xD;
             (according to Cockcroft and Gault formula); D) Urine routine / 24-hour protein&#xD;
             quantification: qualitative urine protein ≤1+ (if qualitative urine protein ≥2+, 24&#xD;
             hours &lt; 1g can be included); E) Cardiac function: left ventricular ejection fraction&#xD;
             ≥50%; F) Coagulation function: International standardized ratio (INR) ≤1.5×ULN, and&#xD;
             activated partial thrombin time (APTT) ≤1.5×ULN;&#xD;
&#xD;
         10. Eligible patients (male and female) who are fertile must agree to use a reliable&#xD;
             contraceptive method (hormonal or barrier method or abstinence, etc.) with their&#xD;
             partner during the trial and for at least 6 months after the last medication;Women of&#xD;
             childbearing age must have a negative blood or urine pregnancy test within 7 days&#xD;
             prior to the first use of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Colorectal cancer patients with HER2 positive (immunohistochemical +++, or&#xD;
             immunohistochemical ++ with FISH amplification);&#xD;
&#xD;
          2. Have received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy&#xD;
             and other anti-tumor therapy within 4 weeks prior to the first use of the study drug,&#xD;
             except the following:&#xD;
&#xD;
             Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first&#xD;
             administration of the study drug or within the 5 half-lives of the drug (whichever is&#xD;
             longer); The traditional Chinese medicines with anti-tumor indications were within 2&#xD;
             weeks before the first use of the study drug;&#xD;
&#xD;
          3. Received an unmarketed clinical investigational drug or treatment within 4 weeks prior&#xD;
             to the first use of the investigational drug;&#xD;
&#xD;
          4. Has undergone major organ surgery (excluding needle biopsy, tracheotomy, gastrostomy,&#xD;
             etc.) or has significant trauma within 4 weeks before the first use of study drugs, or&#xD;
             needs to undergo elective surgery during the trial;&#xD;
&#xD;
          5. Previous recipients of allogeneic hematopoietic stem cell transplantation or organ&#xD;
             transplantation;&#xD;
&#xD;
          6. A history of serious cardiovascular and cerebrovascular diseases, including but not&#xD;
             limited to:&#xD;
&#xD;
             Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias&#xD;
             requiring clinical intervention, grade iii atrioventricular block, etc.&#xD;
&#xD;
             In the resting state, QT interval was prolonged (QTc &gt; 450 msec in men or QTc &gt; 470&#xD;
             msec in women); Acute coronary syndrome, congestive heart failure, aortic dissection,&#xD;
             stroke or other grade 3 or higher cardio-cerebrovascular events within 6 months prior&#xD;
             to the first administration; New York Heart Association (NYHA) heart function grade&#xD;
             ≥II heart failure;&#xD;
&#xD;
          7. Active autoimmune and inflammatory diseases, such as systemic lupus erythematosus,&#xD;
             inflammatory bowel disease, etc., except type I diabetes, hypothyroidism that can be&#xD;
             controlled only with replacement therapy, and skin diseases that do not require&#xD;
             systemic treatment (e.g., vitiligo, psoriasis);&#xD;
&#xD;
          8. A history of other malignant tumors within 3 years prior to the first administration,&#xD;
             with no signs of recurrence and metastasis;&#xD;
&#xD;
          9. Poorly controlled hypertension (systolic blood pressure &amp; GT;150 mmHg or diastolic&#xD;
             pressure &amp;gt;100 mmHg);&#xD;
&#xD;
         10. Pulmonary disease defined as grade 3 or higher according to CTCAE V5.0;Patients with&#xD;
             past or present interstitial lung disease (ILD);&#xD;
&#xD;
         11. Cerebral parenchymal or meningeal metastases with clinical symptoms are not suitable&#xD;
             for inclusion by the investigator;&#xD;
&#xD;
         12. Had ≥ grade 3 infusion-related reactions during prior anti-EGFR antibody therapy&#xD;
             (Cohort_B only);&#xD;
&#xD;
         13. There are known allergic contraindications to any excipients of SI-B001 and&#xD;
             chemotherapeutic agents selected in this study;&#xD;
&#xD;
         14. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active&#xD;
             hepatitis B virus infection (HBV-DNA copy number &gt; 104) or hepatitis C virus infection&#xD;
             (HCV-RNA &gt; center detection lower limit);&#xD;
&#xD;
         15. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia,&#xD;
             sepsis, etc.;&#xD;
&#xD;
         16. Pregnant or lactating women;&#xD;
&#xD;
         17. Persons with mental disorders or poor compliance;&#xD;
&#xD;
         18. The investigator considers that the subject has a history of other serious systemic&#xD;
             diseases or other reasons and is not suitable to participate in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weijian Guo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+86-13980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao</last_name>
    <phone>+86-15013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

